Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) EPS (Weighted Average and Diluted): 2009-2024

Historic EPS (Weighted Average and Diluted) for Gyre Therapeutics (GYRE) over the last 8 years, with Dec 2024 value amounting to $0.05.

  • Gyre Therapeutics' EPS (Weighted Average and Diluted) rose 200.00% to $0.03 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.08, marking a year-over-year increase of 105.48%. This contributed to the annual value of $0.05 for FY2024, which is 103.55% up from last year.
  • Per Gyre Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at $0.05 for FY2024, which was up 103.55% from -$1.41 recorded in FY2023.
  • In the past 5 years, Gyre Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of $0.05 in FY2024 and a low of -$2.87 during FY2021.
  • For the 3-year period, Gyre Therapeutics' EPS (Weighted Average and Diluted) averaged around -$0.54, with its median value being -$0.26 (2022).
  • In the last 5 years, Gyre Therapeutics' EPS (Weighted Average and Diluted) slumped by 442.31% in 2023 and then spiked by 103.55% in 2024.
  • Yearly analysis of 4 years shows Gyre Therapeutics' EPS (Weighted Average and Diluted) stood at -$2.87 in 2021, then spiked by 90.94% to -$0.26 in 2022, then slumped by 442.31% to -$1.41 in 2023, then spiked by 103.55% to $0.05 in 2024.